Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombomodulin alfa

Drug Profile

Thrombomodulin alfa

Alternative Names: MB-015; MR-33; TMD1-105; Trodulin

Latest Information Update: 02 Feb 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Class Anti-inflammatories; Anticoagulants; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Thrombosis
  • Discontinued Disseminated intravascular coagulation

Most Recent Events

  • 02 Feb 2004 No development reported - Preclinical for Thrombosis in USA (unspecified route)
  • 04 Dec 2002 Discontinued - Preregistration for Disseminated intravascular coagulation in Japan (unspecified route)
  • 22 Jun 1998 Phase-III clinical trials for Disseminated intravascular coagulation in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top